Literature DB >> 30257970

Three differently timed presentations of dermatomyositis associated with advanced ovarian cancer.

Michael Flynn1, Zoe Ottaway1, Jasvinder Kaur1, Justin Waters1.   

Abstract

Each of the three patients reported in this article presented with dermatomyositis at various stages of their advanced ovarian cancer. Dermatomyositis was the presenting feature and preceded the diagnosis of ovarian cancer by several months in one patient. In another patient, dermatomyositis occurred just prior to the scheduled third cycle of palliative chemotherapy after surgical debulking for stage 4 disease. The third patient presented with pathognomonic diagnostic features of dermatomyositis after ovarian cancer recurrence. Diagnosis was delayed in at least two of these patients; however, once appropriately diagnosed, each patient responded well to immunomodulatory treatment. In one patient, initiation of oral prednisolone seemed to correlate with a steady improvement in her proximal myopathy. A pulsed methylprednisolone approach was used in another patient with conversion to a tapering dose of oral prednisolone to good effect. In the patient in whom the most severe myopathy affecting bulbar muscle groups was demonstrated, an infusion of 5 days of intravenous immunoglobulin produced an eventual improvement in her steroid-refractory myopathy. © BMJ Publishing Group Limited 2018. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  chemotherapy; gynecological cancer; musculoskeletal syndromes

Mesh:

Substances:

Year:  2018        PMID: 30257970     DOI: 10.1136/bcr-2017-222627

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  2 in total

1.  Rare Features of Dermatomyositis in a Patient with Ovarian Cancer.

Authors:  Lissandra Dal Lago; Frédéric Vandergheynst; Ahmad Awada; Thierry Pepersack
Journal:  Eur J Case Rep Intern Med       Date:  2020-12-15

2.  Retrospective Analysis of Cancer-Associated Myositis Patients over the Past 3 Decades in a Hungarian Myositis Cohort.

Authors:  Csilla András; Levente Bodoki; Melinda Nagy-Vincze; Zoltán Griger; Emese Csiki; Katalin Dankó
Journal:  Pathol Oncol Res       Date:  2019-10-23       Impact factor: 3.201

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.